Overview

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

The project is a Phase III, randomized, open-label, multicenter study in which approximately 36 patients with unresectable Stage III ALK positive Lung Adenocarcinoma will be randomized 1:1 to receive lorlatinib or concurrent/sequential platinum-based chemoradiotherapy

Phase:

PHASE3

Details

Lead Sponsor:

Guangdong Association of Clinical Trials

Treatments:

lorlatinib